Cardiology Update 2025

VOLUME 1

Preventive Cardiology (Section - 1)

1 Improving community level cardiac health awareness through school based education programs in India

2 Air Pollution & CVD in India: Current Perspective

3 Can we cancel out the excess Cardiovascular Risk Caused by Chronic Kidney Disease

4 Smoking Cessation: Never too Early, Never too Late



Hypertension (Section - 2)

5 Implications of Systolic Blood Pressure Time in Target Range

6 Artificial Intelligence - A Potential Tool in the Diagnosis and Management of Hypertension

7 Clinical Management of Primary Aldosteronism

8 Implications of Myocardial Interstitial Fibrosis in Hypertensive Heart Disease

9 Renovascular Hypertension: Kidney Intrinsic Mechanisms as Novel Targets

10 The Complexity of Resistant and Refractory Hypertension



Cardiometabolic (Section - 3)

11 Slowing cardiovascular aging by promoting cardiometabolic health

12 Obesity and Cardiovascular Disease

13 Myocardial Abnormalities Across the AHA - ACC Heart Failure Spectrum in Diabetic Patients



Dyslipidemia Management (Section - 4)

14 Implications of lipid lowering therapy for premature CAD

15 The challenges in reducing Non-HDL- cholesterol.

16 Particle Number and Characteristics of Lipoprotein(a), LDL, and apoB: Contributions to ASCVD

17 Impact of Childhood Non-HDL Cholesterol and LDL Cholesterol on Adult Atherosclerotic Cardiovascular Events



Heart Failure (Section - 5)

18 WHF - How to Predict and Treat Early

19 Pulmonary hypertension in heart failure

20 Progression from Pre-Heart Failure, Heart Stress to Subclinical Heart Failure

21 Human immunology of heart failure

22 Identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure

23 Risk Scores in the Management of Heart Failure

24 Issues in Reversing Advanced Heart Failure

25 Early initiation of GDMT in HF

26 Mixed Cardiogenic-Vasodilatory Shock

27 Chronic right-sided heart failure and tricuspid regurgitation

28 Neuromodulation interventions in the management of heart failure

29 Congestion and Diuretic Resistance in WHF

30 Role of Imaging in Heart Failure Risk Stratification

31 Can Left Ventricular Wall Strain predict Heart Failure?

32 Medical therapy of cardiogenic shock

33 From Pre-shock to Classic Cardiogenic Shock

34 Triaging of Patients of ADHF

35 Gut hypothesis of heart failure: role of gut microbiota-derived metabolites

36 Strategies for Diuretic Intensification in Acute Heart Failure

37 Approaches in Heart Failure With Mildly Reduced and Preserved Ejection Fraction

38 Characteristics and Outcomes of Patients with Valvular Cardiogenic Shock

39 Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure



Cardiomyopathy (Section - 6)

40 Risk Predictors of Sudden Cardiac Death in Hypertrophic Cardiomyopathy

41 Monogenic to Polygenic Clinical Genetic Testing in Hypertrophic Cardiomyopathy

42 Dual Ischemic and Nonischemic Cardiomyopathy

43 Predicting Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy by Myocardial Strain

44 Role of Clonal Haematopoiesis in the Pathogenesis of Dilated Cardiomyopathy

45 Dilated Cardiomyopathy in Systemic Immune-Mediated Diseases

46 Arrhythmia induced Cardiomyopathy

47 Alcoholic Cardiomyopathy



Congenital Heart Disease (Section - 7)

48 The Expanding Future of Sinus Venosus ASD Closure

49 Congenital Heart Disease Across the Lifespan: Clinical Risk Assessment and Prediction

50 Early Intervention for Tetralogy of Fallot

51 Novel Imaging Techniques for Congenital Heart Disease

52 Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease

53 Recent advances in the management of Adult Congenital Heart Disease-Related Heart Failure

54 Congenital Heart Disease in India: The Evolving Landscape

55 Echocardiography for Childhood Left Ventricular Noncompaction

56 Adults with congenital heart disease_ what every cardiologist should know about their care

57 Repaired Tetralogy of Fallot: Quest for a Lifelong Pulmonary Valve



Valvular Heart Disease (Section - 8)

58 Multiparametric Approach to Asymptomatic Aortic Stenosis

59 Secondary Mitral Regurgitation Phenotypes

60 Mitral Annular Disjunction in Mitral Valve Prolapse

61 An Update on High-Gradient "Moderate" Aortic Stenosis

62 Comprehensive Risk Phenotyping in Aortic Stenosis

63 When to Treat Young and Low-Risk Patients with Aortic Stenosis

64 Rheumatic Fever and Rheumatic Heart Disease Continuum: Recent Advances

65 Comprehensive Approach to Aortic Valve Pathophysiology by Fibro-Calcific Imaging

66 ESC 2025 Guidelines on Valvular Heart Disease

67 RHD in India: Current Perspective



Cardio-Obstetrics (Section - 9)

68 Cardiac Interventions in Pregnancy

69 Antepartum CV risk assessment and management of high-risk cardiac delivery.

70 Understanding and Managing Heart Failure during Pregnancy - What's New in Peripartum Cardiomyopathy

71 Hypertensive Disorder of Pregnancy and Long-Term Cardiovascular Outcome

72 Understanding and Managing Anticoagulation during Pregnancy in Women with Heart Valves



Coronary Artery Disease (Section - 10)

73 Sarcopenia in Coronary Microvascular Dysfunction

74 Spontaneous Coronary Artery Dissection

75 Influence of Platelet biology and function on plaque erosion vs rupture

76 Coronary Artery Aneurysms

77 Atherosclerosis, Aortic Dissection, and Peripheral Artery Disease: New Therapeutic Targets





Cardiac Arrhythmia (Section - 11)

78 Stable VT in Ischemic Cardiomyopathy and LVEF < 35%: Ablation vs ICD

79 Long-term CV Outcome of Atrial Fibrillation

80 Effect of Left Atrial Dyssynchrony on Long-term Clinical Outcome during Cardiac Resynchronization Therapy

81 Real World Management of Cardiac Implantable Electronic Device Infections

82 Past, Present and Future of Leadless Pacing

83 Atrial fibrillation in Hf. Role of catheter ablation

84 Ablation of Ventricular Tachycardia in Emergency Situations

85 Prevention of Sudden Cardiac Death Beyond Automated External Defibrillators and Implantable Cardioverter Defibrillators

86 Current Perspective of Pulsed Field Ablation

87 Para-Hisian Ventricular Arrhythmias



Imaging (Section - 12)

88 Risk Stratification with CCTA derived Fractional Flow Reserve and Fractional Flow Reserve Gradient

89 Multi-modality Imaging in Multiple Valvular Heart Diseases

90 Role of LA Indices in the Management of Chronic Severe Aortic Regurgitation

91 Application of Emerging Hybrid Intracoronary Imaging Technologies in Clinical Practice and Research

92 Current Concepts and Clinical Implications of Coronary Artery Calcification

93 Cardiac CT: Emerging Role in Microvascular Dysfunction

94 Role of Cardiac Imaging for Optimizing Medical Therapy





VOLUME 2

STEMI (Section - 13)

95 P2Y12 Inhibitor Pretreatment in STEMI

96 STEMI Revascularization in India: Lessons Learnt from Punjab

97 Cardiac Magnetic Resonance Evaluation of LV Remodeling after Myocardial Infarction

98 Recurrent Thrombosis after Myocardial Infarction

99 STEMI Revascularization in India: Lessons Learnt from Tamil Nadu - 5 years experience

100 Thrombolysis in STEMI in Primary PTCA Era - Current Relevance in India

101 STEMI Revascularization in India: Lessons Learnt from Goa

102 Role of Novel Risk Factors in STEMI Among Young Women.

103 Transition from ST-Segment Elevation MI to Occlusion MI.

104 STEMI Revascularization in India: Role of Thrombolysis in Ambulance

105 Addressing delays in reperfusion therapy - Developing Chest Pain Clinics - A new initiative from STEMI India

106 Advanced Cardiac Patches in the Treatment of Myocardial Infarction



Coronary Intervention (Section - 14)

107 Thrombus Aspiration in Primary Angioplasty

108 Evaluation of Microvascular Dysfunction during Diagnostic Coronary Angiography

109 Prevention of progression of obesity and Cardiometabolic Disease: Intervention in School-Aged Children

110 Perforations in Complex PCI

111 Coronary Physiology by different Approaches for Guiding PCI

112 Left Main Bifurcation ISR - What to do?

113 Management of Drug - Eluting Stent In-Stent Restenosis

114 Bailout Strategies in CTO PCI

115 Metalless PCI

116 Percutaneous coronary intervention in high risk renal disorders:strategies for renal protection

117 Effect of Anatomical and Viability - Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy

118 Dual Antiplatelet Therapy in CKD: Duration and Bleeding Risk in Post PCI Patients

119 Technological Progress in Treating Calcified Lesion

120 PCI in Multivessel Coronary Artery Disease - Outcome According to the Coronary Lesion Complexity



Structural Intervention (Section - 15)

121 Transcatheter Aortic Valve Replacement in Heart Failure

122 Antithrombotic Selection Post - Left Atrial Appendage Occlusion

123 Predictors of Outcome of Re-interventions after TAVR

124 Implications of Left Bundle Branch Block in Aortic Stenosis beyond Pacemaker Implantation

125 Imaging of Transcatheter Valve Failure: An Update

126 Transcatheter Treatment of Pure Aortic Regurgitation

127 Transcatheter Mitral Therapy: Changing Context and Goals

128 Unveiling Right Ventricle Remodeling Following Tricuspid Valve Intervention

129 Resolving the Unmet Need for Treatment of Tricuspid Regurgitation

130 Bleeding after Transcatheter Structural Valve Interventions



HOT TOPICS (Section - 16)

PART 1: Heart Failure

131 Mitral Regurgitation in HF

132 Heart Failure and Aging

133 How does the Discontinuation of Long-Term Drug Treatment affectPatients With HFrEF

134 Metabolic defects in HFpEF and how to tackle them

135 Timing of Physical Activity and its impact on Cardiovascular Health

136 Impact of the EAT-Lancet Diet in Preventing Heart Failure

137 Cardiac Cachexia: Controversies and Conundrums

138 Therapeutic Inertia in the Treatment of HFrEF

139 ARNI-Induced Hypotension in HFrEF

140 The issue of Mortality Reduction in Patients With HFmrEF and HFpEF

141 HFrEF & HFpEF how they differ in advanced heart failure: A global perspective

142 Decongestion in acute heart failure: beyond diuretic-centred paradigm

143 Hepatic Biomarker Abnormalities in the Cardiac Intensive Care Unit Proposed Criteria for Cardiohepatic Syndrome

144 Bridging Atrial and Ventricular Failure Through Biomarkers

145 Ambulatory Advanced Heart Failure: Therapeutic Options

146 Interaction between Hypoalbuminemia and HF

147 Implications of Atrial Fibrillation for GDMT in Heart Failure

148 Challenges in Modifying Kidney Disease Progression in Patients With Heart Failure

PART 2: Hypertension

149 Impact of Supranormal Left Ventricular Ejection Fraction, Concentric Remodeling in the Long-Term Survival

150 Brain Pathways in Regulating Blood Pressure

151 Update on Low-Renin Hypertension

152 Sodium, Interstitium, Lymphatics and Hypertension

153 Arterial Stiffness and Chronic Kidney Disease

PART 3: Coronary Artery Disease

154 Coronary Artery Spasm and Atherosclerotic Cardiovascular Disease

155 Peri-Infarct Ischemia and its Prognostic Significance

156 Hemorrhagic Myocardial Infarction

157 The issue of Stent Failure After PCI in patients with Diabetes Mellitus

158 Red blood cells as a new target for ASCVD prevention

159 Residual Chest Pain After PCI

PART 4: Dislipidemia Management

160 HDL enhancing strategies and prevention of ASCVD

161 Cholesterol Screening and Management in Young Adults

PART 5: Ischaemic Heart Disease

162 Vitamin D and Cardiovascular Risk

163 Testosterone and Cardiovascular Health

164 Primary Prevention for Intermediate CV Risk

165 Exposome in ischaemic heart disease

166 Interaction between Dietary Calcium and Vascular Calcification

167 Rethinking Beta Blocker in Stable Coronary Artery Disease

PART 6: Structural Intervention

168 PFO Closure for Stroke Prevention: An Illusion of Safety

PART 7: Heart & Brain

169 Role of Left Atrial Stiffness in the evaluation of Cryptogenic Stroke

PART 8: Cardiac Arrythmia

170 Appropriate use of defibrillator in non-ischaemic cardiomyopathy

171 Predicting Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: role of Radiomics

172 Anticoagulation for atrial fibrillation in patients with intermediate stroke risk

173 Digging up Digoxin: Should We Stop Prescribing it? Current views and perspectives

PART 9: Amyloidosis

174 Prognostic role of Amyloid burden

175 Predictors of outcome in AL Amyloidosis Patients With Cardiac Involvement



Top 10 Papers (Section - 17)

176 Top 10 Papers in diabetes and metabolic disorders

177 Top 10 Papers in Anti-thrombotic

178 Top 10 papers in Lipids

179 Top 10 papers in Intervention



Viewpoint (Section - 18)

PART 1: Obesity Paradox is a Fact

180 An Unexpected Relationship Between Body Weight and Health Outcomes (Proponent)

181 Myth or Reality (Opponent)

PART 2: Time Matters when Considering Treatment for Patients with Mitral Regurgitation

182 Time Matters When Considering Treatment for Patients with Mitral Regurgitation (Proponent)

183 Time Matters When Considering Treatment for Patients with Mitral Regurgitation (Opponent)

184 CHAD-VASC of 1 Not Same for Every Patient with Afib

185 How to Resolve the Prosthesis - Patient Mismatch Debate

186 AI will Replace Clinical Cardiology



Miscellaneous (Section - 19)

187 Takayasu Arteritis - What is New?

188 Treatment of OSA & its impact on CVD

189 Participation in Sports by Athletes with CVD

190 Donor Selection for Heart Transplantation

191 Antithrombotic Therapies in Patients with Peripheral Artery Disease

192 Cardiology Training in India - Past Present and Future

193 Native Valve Infective Endocarditis: Recent Insights

194 Pulmonary Arterial Hypertension - no longer an orphan disease

195 Enigmas of the Athletic Heart

196 Cardiac Sarcoidosis: Diagnosis and Management

197 Marantic Endocarditis

198 Epilepsy and the heart: interaction between 'brain arrhythmia' and cardiac arrhythmia